Evista Approval For Breast Cancer Risk Reduction Comes With “Black Box” On VTE, Stroke
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly’s osteoporosis drug is cleared for use in reducing the risk of invasive breast cancer in two female patient populations.
You may also be interested in...
Lilly Licenses Hormone Patch For Osteoporosis
Lilly Licenses Hormone Patch For Osteoporosis
Lilly Licenses Hormone Patch For Osteoporosis
Lilly Licenses Hormone Patch For Osteoporosis
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative
Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.